SCHD offers better diversification, with no single position exceeding 4.4% of the portfolio, compared to HDV's 10% in ExxonMobil. SCHD has a lower expense ratio compared to HDV and has achieved ...

Gilead Sciences has been knocked back in its quest to bring the first drug therapy for hepatitis D virus (HDV) to the US market, after the FDA rejected its marketing application. News of the ...

Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. Leverage the Nasdaq+ Scorecard to analyze stocks based on your investment priorities and our market data.